Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Three-way, Cross-over Study to Assess the Efficacy of a Dual-hormone Closed-loop System With XeriSol Glucagon vs Closed-loop System With Insulin Only vs a Predictive Low Glucose Suspend System

Next Previous
Trial Profile

A Randomized, Three-way, Cross-over Study to Assess the Efficacy of a Dual-hormone Closed-loop System With XeriSol Glucagon vs Closed-loop System With Insulin Only vs a Predictive Low Glucose Suspend System

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glucagon (Primary) ; Insulin aspart
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use

Most Recent Events

  • 09 Sep 2020 Primary endpoint (Percent of time with sensed glucose 70 mg/dl) has been met.
  • 09 Sep 2020 Results published in the Diabetes Care
  • 11 Jun 2019 Interim analysis results (n=7) evaluating the safety of Xerisol are presented at the 79th Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top